Dr. Aline Herlopian
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 424
Licensed in Connecticut since 2017, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CT license 56303 (first issued 2017; active) -
Clinical Neurophysiology Physician
CT license 56303 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Bridgeport Hospital Bridgeport, CT
- Greenwich Hospital Association - Greenwich, CT
- Griffin Hospital Derby, CT
- Lawrence & Memorial Hospital New London, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 424
- Services billed
- 860
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 167 | 114 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 98 | 74 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 69 | 69 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 69 | 64 |
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 24 |
| Measurement of brain wave activity (eeg), 41-60 minutes | 32 | 32 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 25 | 22 |
| Measurement of brain wave activity (eeg), 12-26 hours with health care professional review and report | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobazam | 552 |
| Levetiracetam Other prescribers in New Haven, CT | 397 |
| Briviact (brivaracetam) | 394 |
| Lamotrigine Other prescribers in New Haven, CT | 372 |
| Lacosamide Other prescribers in New Haven, CT | 236 |
| Xcopri (cenobamate) | 235 |
| Divalproex Sodium Other prescribers in New Haven, CT | 189 |
| Lamotrigine Er (lamotrigine) Other prescribers in New Haven, CT | 187 |
| Carbamazepine Er (carbamazepine) Other prescribers in New Haven, CT | 170 |
| Topiramate Other prescribers in New Haven, CT | 148 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 12 payments worth $3,726 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $3,581 |
|---|---|
| Sk Life Science, Inc. | $89.20 |
| Acadia Pharmaceuticals Inc | $56.59 |
| Consulting Fee | $1,893 |
|---|---|
| Travel and Lodging | $1,337 |
| Food and Beverage | $496 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. May 21, 2025 | Consulting Fee EPIDIOLEX · NEUROLOGY | $1,893 |
| Jazz Pharmaceuticals Inc. Sep 12, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Phoenix, AZ · in-kind | $829 |
| Jazz Pharmaceuticals Inc. Sep 12, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Phoenix, AZ · in-kind | $256 |
| Jazz Pharmaceuticals Inc. Sep 12, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Phoenix, AZ · in-kind | $252 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $254,231 in research payments for these studies, mostly to the institutions running them.
- A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Ol…
Jazz Pharmaceuticals Inc. - YKP3089C049
Sk Life Science, Inc. - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Terminated · NCT04686786 - A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Completed · NCT04244175 - A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset…
Jazz Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.